Country Onco Overview ARGENTINA

Summary presentation

I. Profile

II. Business definition

III. Where does Teva Oncology stand?

IV. Areas of performance and where demand can be grown

V. Barriers to success

VI. Maximising opportunities with customers across the portfolio

VII. Disruptive opportunities

Selfie

First and last name: Josefina Gaeta Country: ARGENTINA

Role :Marketing Director Specialties

Something I’d like to share ….. “ I am very proud of my guiding stars : Sofia and Mateo”

My expectations for this meeting are :1- Create a common TEVA ONCOLOGY vision fully oriented to patients 2- Create disruptive moves that will positioned TEVA as the best in class Pharma company

Selfie

First and last name: Brenda MazzaferriCountry: Argentina

RoleMedical Advisor Oncology

Something I’d like to share with the team… ideas and experiences .

My expectations for this meeting are…I believe that this meeting is essential in the career building as well as an opportunity for brainstorming in order to generate new ideas and perspectives that could lead to new medical solutions.

Selfie

First and last name: Alejandro CottaCountry: Argentina

RoleSpecialties Marketing Manager

Something I’d like to share with the team is…

We are building our success

My expectations for this meeting are…Sharing of best practices and take home the best ones for implementing them locally.

II. Business definition - Oncology Market : Total Market 1.0 USD M

Top 15 brands , company, sales (MAT 03/2015 vs MAT 03/2014) & growth

Total Market: 1.033 USD MTop 15 Brands = 44 % MS Values

Market Access and Services (reimbursement/out of pocket, national program /preference, early diagnosis etc.)A.Oncology products (QT) are 100 % reimbursedB. Supportive care products (GCSFs, nutrition, antiemethics, etc) are not covered by healthcare system and need special authorization to be reimbursed by Health SystemC.National Oncology Program for indigents

Brand Company Sales USD K Growth

AVASTIN ROCHE 74,063 7,4%

MABTHERA ROCHE 72,021 8,1%

HERCEPTIN ROCHE 58,738 15,6%

ERBITUX MERCK SERONO 39,344 0,5%

VELCADE JANSSEN CILAG 36,600 -0,6%

REVLIMID RAFFO 23,936 16,7%

VIDAZA VARIFARMA 21,751 30,2%

SUTENT PFIZER 21,637 16,9%

GLIVEC NOVARTIS 19,801 0,0%

AFINITOR NOVARTIS 19,597 -14,6%

ZYTIGA JANSSEN CILAG 18,747 -3,4%

LECTRUM SANDOZ 16,022 -6,2%

ELIGARD RAFFO 12,807 6,3%

NEXAVAR BAYER 12,420 8,4%

TASIGNA NOVARTIS 11,693 7,7%

Channel (Hospital/clinic/private/government/major source of sales %) A.SOCIAL SECURITY 59% B.GOVERNMENT 36% C.PRIVATE 5%

III. Where does Teva Oncology stand? BGx Products

Onco Company ranking & growth Brand Sales $K2015

Sales $K2016

Market share

Launch year

Abelcet * 2,253 2,348 41% 2014

BCG * 1,208 1,125 20% 1997

Taycovit 707 713 12%

Prostene 560 403 7%

Platinostyl 132 115 2%

Elmiron 144 108 2%

Dicladox 114 102 2%

CPD 117 93 2%

Carboplatino Ivax

117 77 1%

Vetio 68 58 1%

Noxetol 52 54 1%

Hemalen 0 50 1% 2016

Multizom 0 78 1% 2016

Company Sales $K2015

Ranking Growth

ROCHE 226,074 1 11%

RAFFO 72,010 2 20%

NOVARTIS 69,910 3 2%

LKM 69,366 4 43%

TUTEUR 66,833 5 505

JANSSEN CILAG 61,632 6 -2%

VARIFARMA 47,432 7 40%

PFIZER 39,806 8 28%

MERCK SERONO

39,344 9 1%

BAYER 34,298 10 19%

SANDOZ 30,046 11 -13%

* Innovative

IV. Areas of performance and where demand can be grown (1)

Category, access, channel, trends, government policy, patient association (cooperation ?) Argentine healthcare system has more than 300 HMO. It´s a mixed System: Private and Governmental, more than 60 % of population are covered by Gov. System. Oncology is covered 100 %For BGx main driver is price and be E2M, for innovative the main driver is related to the inclusion of the molecule in the National formulary to start the reimbursement process with each HMO . Accesses is crucial at this stage .Trends: Payors are increasing their power in the decision process due to budget restrictions. For innovative drugs Risk-sharing agreements will continue to gain momentum.

Core business vs. new segments/products, new targets etcNew Products: ASTRODIL ( Abiraterone) will be launched Q1 2017 as part of the strategy of extension lineNew TA and also new target: Oncohematology : Launch of 2 BGx in 2016 : MULTIZOM ( Bortezomib) and HEMALEN ( Lenalidomide) and AZATEVA ( Azacitidine) in 2017. Lonquex will be launched in Q1-2017.

IV. Areas of performance and where demand can be grown (2)

Country asset audit - what assets/resources implemented in your market were a success? (List branded and unbranded resources/assets - Med Ed, patient support programs, CRM, TPP/owned sites, apps, games, etc.) Your listed assets will be compiled to create an internal depository that all countries can use.

Our main asset is CME: Train the Trainers and Speaker program ( ABELCET)

What additional assets/resources can be developed to further grow demand? - Create a patient centric approach program and a digital platform to educate both patients and doctors, and

also to monitor treatment.- Access strategy is crucial to get reimbursement , Value Dossier will be needed for some products. - As part of premarketing activities, the role of MSL will be also crucial.- Market research for new TA.

Competitor threats • Multinational companies

are well positioned and have strong pipelines

• Local players : • Strong BGx´s

portfolio. Some of them have products under licenses (Revlimid and Vectibix/Raffo, Vidaza/Varifarma)

• They are F2M BGx

V. Barriers to success – What keeps you awake at night?

Customer attitudes and behavior• Payer management is likely to

become more restrictive for oncologics (increasing numbers of PAs) with an increased emphasis on comparative effectiveness and cost-shifting to patients. For pharmaceutical companies, this translates into more head-to-head trials and an increasing focus on biomarkers and demonstrating overall cost-effectiveness

• KOLs : Given the small pool of oncologists, thought leaders in the field are more than usually influential,and engaging them in clinical trial design and expanded access programs is critical

Internal/regulatory issues/ portfolio

• Complex and changing regulatory environment may delay approvals by ANMAT.

• New products licenses are very important in order to have a strong portfolio to compete in this market

• Targeted treatments ( Mabs) with sequencing indication is the future for our success in Oncology.

For example, creating synergies with high-value brands and BGx/Gx within the same therapeutic areas.

TEVA´s portfolio in Argentina is obsolete, we are currently in the process of building a new one. We don´t have high values Brands.

A Brand like Lonquex ( world wide recognized) will help us to leverage TEVA image and also with create synergies with other products.

VI. Maximizing opportunities with customers across the portfolio

VII. Disruptive/Critical Mass opportunities – The sky is the limit

For Oncology , Hematology, Customers, Channels, Access, Products, Services etc

Disruptive opportunities- Develop digital platform “Teva Campus” that will offer physicians high impact services : clinical trials, real

world evidence, access support, etc.- Sponsorship of awareness campaign to leverage early Ca detection , working together with Oncology

Medical Societies and Patients Associations.- Patients Advocacy Groups where Cancer patients are physicians. This group of “ Special” patients will then

talk to other patients and to doctors. Critical Mass⁻ Local competitor (with focus on Oncology, Oncohematology & HIV –if possible-) acquisition⁻ Develop of Mabs in agreement with local Universities⁻ Develop the best in class biomarker portfolio